Eunju Hurh
About
Eunju Hurh is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Eunju Hurh has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eunju Hurh's work include Lipid metabolism and disorders (7 papers), Hedgehog Signaling Pathway Studies (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Eunju Hurh is often cited by papers focused on Lipid metabolism and disorders (7 papers), Hedgehog Signaling Pathway Studies (7 papers) and Lipoproteins and Cardiovascular Health (4 papers). Eunju Hurh collaborates with scholars based in United States, France and Switzerland. Eunju Hurh's co-authors include Sotirios Tsimikas, Richard S. Geary, Joseph L. Witztum, James T. Dalton, Duane D. Miller, Veeresa Gududuru, Louis O’Dea, Steven G. Hughes, Veronica J. Alexander and Rosie Z. Yu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.
In The Last Decade
Eunju Hurh
42 papers receiving 2.2k citations
Hit Papers
Peers
Eunju Hurh
Anthony E. Dear Australia
Takako Asano Japan
Mark Wickens United Kingdom
Frank Himmelsbach Germany
Giuliana Cassinelli Italy
Jean Charles Soria France
Brigitte Kaiser Germany
Connie L. Erickson‐Miller United States
Sabine Käyser Germany
Noboru Nakaigawa Japan
Citations per year, relative to Eunju Hurh Eunju Hurh (= 1×)
peers
Anthony E. Dear
Countries citing papers authored by Eunju Hurh
Since
Specialization
Citations
This map shows the geographic impact of Eunju Hurh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eunju Hurh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eunju Hurh more than expected).
Fields of papers citing papers by Eunju Hurh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eunju Hurh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eunju Hurh. The network helps show where Eunju Hurh may publish in the future.
Co-authorship network of co-authors of Eunju Hurh
This figure shows the co-authorship network connecting the top 25 collaborators of Eunju Hurh. A scholar is included among the top collaborators of Eunju Hurh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eunju Hurh. Eunju Hurh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 160TiP A phase I/II study of CFT1946, a novel BIDAC degrader targeting mutant BRAF V600 solid tumors including metastatic colorectal cancer (CRC) in combination with cetuximab. Annals of Oncology. 35. S71–S72.
2.
Vieito, María, Ezra Y. Rosen, Jordi Rodón, et al.. (2024). 612O Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors. Annals of Oncology. 35. S490–S491.
3.
Oral, Elif A, Abhimanyu Garg, Joseph A. Tami, et al.. (2022). Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study. Journal of clinical lipidology. 16(6). 833–849.
4.
Foss‐Freitas, Maria Cristina, Barış Akıncı, Adam Neidert, et al.. (2021). Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids in Health and Disease. 20(1). 174–174.
5.
Gaudet, Daniel, Ewa Karwatowska‐Prokopczuk, Seth J. Baum, et al.. (2020). Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal. 41(40). 3936–3945.
6.
Watts, Lynnetta M., Ewa Karwatowska‐Prokopczuk, Eunju Hurh, et al.. (2020). Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers. Nucleic Acid Therapeutics. 30(4). 198–206.
7.
Post, Noah, Rosie Z. Yu, Sarah Greenlee, et al.. (2019). Metabolism and Disposition of Volanesorsen, a 2′-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metabolism and Disposition. 47(10). 1164–1173.
8.
Alexander, Veronica J., Shuting Xia, Eunju Hurh, et al.. (2019). N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal. 40(33). 2785–2796.
9.
Alexander, Veronica J., Andrés Digenio, Shuting Xia, et al.. (2018). INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES. Journal of the American College of Cardiology. 71(11). A1724–A1724.
10.
Graham, Mark J., Richard Lee, Teresa Brandt, et al.. (2017). Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New England Journal of Medicine. 377(3). 222–232.
11.
Shemesh, Colby S., Rosie Z. Yu, Mark S. Warren, et al.. (2017). Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs. Molecular Therapy — Nucleic Acids. 9. 34–47.
12.
Kieran, Mark W., Julia Chisholm, Michela Casanova, et al.. (2017). Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncology. 19(11). 1542–1552.
13.
Rodón, Jordi, Hussein Tawbi, Anne Thomas, et al.. (2014). A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(7). 1900–1909.
14.
Geoerger, Birgit, Isabelle Aerts, María José Casanova, et al.. (2012). UPDATED RESULTS FROM A PHASE I STUDY OF LDE225, A SMOOTHENED ANTAGONIST, IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA OR OTHER SOLID TUMORS. UCL Discovery (University College London).
15.
Dong, Jennifer, David H. Salinger, Christopher J. Endres, et al.. (2011). Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies. Clinical Pharmacokinetics. 50(2). 131–142.
16.
Gududuru, Veeresa, et al.. (2005). SAR studies of 2-arylthiazolidine-4-carboxylic acid amides: A novel class of cytotoxic agents for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 15(18). 4010–4013.
17.
Gududuru, Veeresa, Eunju Hurh, James T. Dalton, & Duane D. Miller. (2005). Discovery of 2-Arylthiazolidine-4-carboxylic Acid Amides as a New Class of Cytotoxic Agents for Prostate Cancer. Journal of Medicinal Chemistry. 48(7). 2584–2588.
18.
Gududuru, Veeresa, Eunju Hurh, James T. Dalton, & Duane D. Miller. (2004). Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 14(21). 5289–5293.
19.
Gududuru, Veeresa, Eunju Hurh, Gangadhar G. Durgam, et al.. (2004). Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 14(19). 4919–4923.
20.
Hurh, Eunju, et al.. (2000). Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous parathion in rats. Biopharmaceutics & Drug Disposition. 21(5). 193–204.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anthony E. Dear Breakdown of academic impact, for papers by Takako Asano Breakdown of academic impact, for papers by Mark Wickens Breakdown of academic impact, for papers by Frank Himmelsbach Breakdown of academic impact, for papers by Giuliana Cassinelli Breakdown of academic impact, for papers by Jean Charles Soria Breakdown of academic impact, for papers by Brigitte Kaiser Breakdown of academic impact, for papers by Connie L. Erickson‐Miller Breakdown of academic impact, for papers by Sabine Käyser Breakdown of academic impact, for papers by Noboru Nakaigawa